The ubiquitin-proteasome system meets angiogenesis

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 538-548

  Rahimi, Nader ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CASEIN KINASE I; DISHEVELLED 1; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; KELCH LIKE 12 E3 LIGASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROTEASOME; PROTEIN KINASE B; RING FINGER PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84859390736     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0555     Document Type: Review

References (102)

1. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
6. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87. (Pubitemid 44435320)
7. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur J Cancer 2009;45:1924-34.
8. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 2007;74:131-44. (Pubitemid 350051023)
9. Bressler NM, Bressler SB, Fine SL. Neovascular (exudative) age-related macular degeneration. In: Ryan SJ, editor. Retina. Vol. 2. St. Louis: Elsevier/Mosby; 2006. p. 1075-113.
10. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40:277-87. (Pubitemid 40942254)
11. Carmeliet P. Mechanism of angiogenesis and arteriogenesis. Nat Med 2000;66:53-8.
12. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84. (Pubitemid 36749216)
13. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549-60. (Pubitemid 43290332)
14. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-75. (Pubitemid 46448066)
15. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol 2005;21:457-83. (Pubitemid 41740643)
16. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273:31273-82. (Pubitemid 28533143)
17. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006;25:373-85. (Pubitemid 44922356)
18. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000;275:16986-92. (Pubitemid 30398939)
19. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006;11:818-29. (Pubitemid 43262905)
20. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellén L, et al. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 2006;10:625-34.
21. Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 2011;286:29913-21.
22. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68. (Pubitemid 30368433)
23. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature 2009;458:422-9.
24. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008;9:679-90.
25. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009;49:73-96.
26. Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, et al. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A 2007;104:5413-8. (Pubitemid 47175694)
27. Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 2001;16;276:4872-8.
28. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009;325:1134-8.
29. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004;5:177-87. (Pubitemid 38325799)
30. Bedford L, Paine S, Sheppard PW, Mayer RJ, Roelofs J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol 2010;20:391-401.
31. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 1998;94:615-23. (Pubitemid 28427580)
32. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001;2:179-87.
33. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
34. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010;30:258-70.
35. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82. (Pubitemid 27043825)
36. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998;92:2260-8. (Pubitemid 28452966)
37. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4. (Pubitemid 33131538)
38. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40. (Pubitemid 33063099)
39. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-206. (Pubitemid 32910914)
40. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
41. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86. (Pubitemid 32988878)
42. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 2007;26:63-74. (Pubitemid 46550936)
43. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999;460:251-6. (Pubitemid 29495950)
44. Liu YV, Semenza GL. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 2007;6:656-9. (Pubitemid 46535675)
45. Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004;1697:233-42.
46. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002;277:29936-44.
47. Lee JM, Lee WH, Kay HY, Kim ES, Moon A, Kim SG. Hemin, an iron-binding porphyrin, inhibits HIF-1a induction through its binding with heat shock protein 90. Int J Cancer 2012;130:716-27.
48. Meyer RD, Singh AJ, Rahimi N. The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling. J Biol Chem 2004;279:735-42. (Pubitemid 38044879)
49. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006;174:593-604. (Pubitemid 44231870)
50. Singh AJ, Meyer RD, Band H, Rahimi N. The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell 2005;16:2106-18. (Pubitemid 40471975)
51. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, Mellor H. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 2006;108:2624-31.
52. Meyer RD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol Cell Biol 2011;31:2010-25.
53. Rahimi N, Kazlauskas A. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. Mol Biol Cell 1999;10:3401-7. (Pubitemid 29489570)
54. Rechsteiner M. PEST sequences are signals for rapid intracellular proteolysis. Semin Cell Biol 1990;1:433-40.
55. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25. (Pubitemid 38737738)
56. Crusio KM, King B, Reavie LB, Aifantis I. The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene 2010;29:4865-73.
57. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature ofmammalian F-box proteins. Genes Dev 2004;18:2573-80. (Pubitemid 39453096)
58. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998;396:590-4. (Pubitemid 28563722)
59. Koike J, Sagara N, Kirikoshi H, Takagi A, Miwa T, Hirai M, et al. Molecular cloning and genomic structure of the betaTRCP2 gene on chromosome 5q35.1. Biochem Biophys Res Commun 2000;269:103-9. (Pubitemid 30440262)
60. Suzuki H, Chiba T, Suzuki T, Fujita T, Ikenoue T, Omata M, et al. Homodimer of two F-box proteins beta TrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination. J Biol Chem 2000;275:2877-84. (Pubitemid 30082062)
61. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, et al. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 2003;4:799-812. (Pubitemid 36676033)
62. Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoé K, Good RA, et al. Impaired degradation of inhibitory subunit of NFkappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA 2003; 100:8752-7. (Pubitemid 36899171)
63. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-g and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768-78. (Pubitemid 32938560)
64. Meyer RD, Latz C, Rahimi N. Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem 2003;278:16347-55. (Pubitemid 36799761)
65. Liao HJ, Kume T, McKay C, Xu MJ, Ihle JN, Carpenter G. Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J Biol Chem 2002;277:9335-41. (Pubitemid 34953017)
66. Covassin LD, Siekmann AF, Kacergis MC, Laver E, Moore JC, Villefranc JA, et al. A genetic screen for vascular mutants in zebrafish reveals dynamic roles for Vegf/Plcg1 signaling during artery development. Dev Biol 2009;329:212-26.
67. Meyer RD, Husain D, Rahimi N. c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCg1. Oncogene 2011;30:2198-206.
68. Husain D, Meyer RD, Mehta M, Pfeifer WM, Chou E, Navruzbekov G, et al. Role of c-Cbl-dependent regulation of phospholipase Cgamma1 activation in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2010;51:6803-9.
69. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001;276:17686-92.
70. Bone HK, Welham MJ. Phosphoinositide 3-kinase signalling regulates early development and developmental haemopoiesis. J Cell Sci 2007;120:1752-62. (Pubitemid 46930413)
71. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-6. (Pubitemid 351769296)
72. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35. (Pubitemid 34155123)
73. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104.
74. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001;2:870-5.
75. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3¢-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43. (Pubitemid 28545503)
76. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-50. (Pubitemid 34787405)
77. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A 2008;105:3622-7. (Pubitemid 351723602)
78. Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell 2009;17:800-10.
79. Toker A. TTC3 ubiquitination terminates Akt-ivation. Dev Cell 2009;17:752-4.
80. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, et al. Negative regulation of AKT activation by BRCA1. Cancer Res 2008;68:10040-4.
81. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000;287:1606-9. (Pubitemid 30127755)
82. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810. (Pubitemid 39488658)
83. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999;18:2401-10. (Pubitemid 29213274)
84. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, et al. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 2008;10:1208-16.
85. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001;7:927-36. (Pubitemid 32525740)
86. Nastasi T, Bongiovanni A, Campos Y, Mann L, Toy JN, Bostrom J, et al. Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev Cell 2004;6:269-82. (Pubitemid 38195218)
87. Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, et al. Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun 2003;309:408-13. (Pubitemid 37025905)
88. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222-31. (Pubitemid 34218196)
89. Funato Y, Terabayashi T, Sakamoto R, Okuzaki D, Ichise H, Nojima H, et al. Nucleoredoxin sustains Wnt/b-catenin signaling by retaining a pool of inactive dishevelled protein. Curr Biol 2010;20:1945-52.
90. Miyazaki K, Fujita T, Ozaki T, Kato C, Kurose Y, Sakamoto M, et al. NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem 2004;279:11327-35. (Pubitemid 38401630)
91. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
92. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243-8. (Pubitemid 28413959)
93. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65-77. (Pubitemid 30051524)
94. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28. (Pubitemid 32708698)
95. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8. (Pubitemid 38174664)
96. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-8. (Pubitemid 40022713)
97. Zhou S, Gu L, He J, Zhang H, Zhou M. MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol 2011;31:4928-37.
98. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91. (Pubitemid 47037522)
99. Critchley S, Gant TG, Langston SP, Olhava EJ, Peluso SMillennium Pharmaceuticals Inc. Inhibitors of E1 activating enzymes. United States patent US WO2006084281. 2007 Oct 31.
100. Parlati F, Ramesh UV, Singh R, Payan DG, Lowe R, Look GCRigel Pharmaceuticals Inc. Benzothiazole and thiazole[5,5-B]pyridine compositions and their use as ubiquitin ligase inhibitors. United States patent US WO2005037845. 2005 Apr 28.
101. Guédat P, Colland F. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 2007;8[Suppl 1]:S14.
102. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem 2008;9[Suppl 1]:S7.